J. Yu

The Curative Effect of ALSS on 1-month Mortality in AoCLF Patients after 72 to 120 Hours

J.-Q. He, W. Du, H. Cao, 2007, The International journal of artificial organs.

A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg‐IFN on Hepatitis C Virologic Response

Thi Huyen Tram Nguyen, J. Guedj, F. Mentré, 2014, Clinical pharmacology and therapeutics.

High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections.

D. Hui, G. Lui, K. Wong, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A rapid pneumococcal serotyping system based on monoclonal antibodies and PCR.

M. Nahm, B. Beall, Jigui Yu, 2008, Journal of medical microbiology.

Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome

F. Mentré, M. Levi, J. Yu, 2013, CPT: pharmacometrics & systems pharmacology.

Pegylated interferon alfa-2a (PEGASYSTM) and ribavirin combination therapy for chronic hepatitis C: A phase II open-label study

M. Sulkowski, R. Reindollar, J. Yu, 2000 .

Association of Time‐Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis

Y. Wang, C. Liu, H. Li, 2017, Clinical pharmacology and therapeutics.

ALISPORIVIR - A HOST-TARGETING ANTIVIRAL, PROVIDES LOW VIRAL BREAKTHROUGH RATE AND HIGH BARRIER TO RESISTANCE IN HCV GENOTYPE 1 TREATMENT-NAiVE PATIENTS IN THE PHASE IIB ESSENTIAL STUDY

Christopher T. Jones, A. Vandamme, J. Snoeck, 2011 .